Yuyu Pharma aims to grow with drugs for dry eye and hair loss

Yuyu Pharma aims to grow with drugs for dry eye and hair loss









the times of korea



Settings



Yuyu Pharma aims to grow with drugs for dry eye and hair loss

Robert Yu, Chairman and CEO of Yuyu Pharma, speaks during a press conference held on the sidelines of the CPHI exhibition in Frankfurt, Germany, on Wednesday.  Joint Press Body
Robert Yu, Chairman and CEO of Yuyu Pharma, speaks during a press conference held on the sidelines of the CPHI exhibition in Frankfurt, Germany, on Wednesday. Joint Press Body

By Baek Byung Yeul

FRANKFURT – Robert Yu, chairman and chief executive officer of Yuyu Pharma, said Wednesday that his mission is to make the company comparable to the world’s leading biopharmaceutical companies. To that end, he said the Korean company is actively diversifying its portfolio by developing new drugs, such as a dry eye treatment and hair loss medication.

“Yuyu Pharma has two projects. One is a dry eye treatment and the other is a medicine for hair loss,” Yu said during a press conference held on the sidelines of the CPHI exhibition in Frankfurt.

“We are currently conducting the Phase 2 clinical trial for the new dry eye drug in the United States with 240 patients. The trial results will be published in the first half of 2023,” he said.

Based on preclinical studies, the company said a dose-dependent decrease in various inflammatory mediators associated with dry eye was observed in the cornea and conjunctiva. These findings indicate that their candidate eye drug YP-P10 may have anti-inflammatory activities on ocular surface inflammation induced by dry eye.

“We are also planning to conduct a clinical trial of our hair loss drug. Dutasteride, familiar to Koreans as Avodart, is actually used to treat an enlarged prostate. However, this drug is widely used as a treatment for hair loss in Korea and Japan. The interesting thing is that there have been no clinical trials on whether it can be used as a medicine for hair loss in Europe and the US,” he said.

“We will hold a meeting with the US FDA (Food and Drug Administration) in the first half of next year to get approval to start clinical trials on whether this drug can be used to treat hair loss. If approved, we will start clinical trials in 2024,” the CEO added.

Yu is the grandson of company founder Yu Teuk-han and the son of current chairman Yu Seung-pil. As a third-generation owner, he said his task is to challenge new drug developments for the future of the company’s next 80 years, which celebrated its 80th anniversary last year.

The company generates its sales mainly from the sale of pharmaceuticals and health supplements, but its financial situation has worsened due to excessive spending on the development of new drugs. In 2021, Yuyu Pharma entered the red with an operating loss of 1.6 billion won (US$1.12 million).

However, Yu said the development of new treatments must continue as it will become a turning point for the company.

“If we stop developing new drugs, we can easily see operating profit immediately. When asked if we are on the right track in the long term, I believe Yuyu Pharma can achieve this. It is not just about taking on new business. I am risking my life for this business,” he said.


























































































































Leave a Comment